BRPI0513303A8 - Uso de l-carnitina para o tratamento de doenças cardiovasculares - Google Patents
Uso de l-carnitina para o tratamento de doenças cardiovascularesInfo
- Publication number
- BRPI0513303A8 BRPI0513303A8 BRPI0513303A BRPI0513303A BRPI0513303A8 BR PI0513303 A8 BRPI0513303 A8 BR PI0513303A8 BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A8 BRPI0513303 A8 BR PI0513303A8
- Authority
- BR
- Brazil
- Prior art keywords
- carnitine
- infarction
- treatment
- grams
- days
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 206010061216 Infarction Diseases 0.000 abstract 2
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000346A ITRM20040346A1 (it) | 2004-07-13 | 2004-07-13 | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| PCT/EP2005/006657 WO2006005415A2 (en) | 2004-07-13 | 2005-06-21 | Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0513303A BRPI0513303A (pt) | 2008-05-06 |
| BRPI0513303A8 true BRPI0513303A8 (pt) | 2017-12-26 |
Family
ID=34971575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513303A BRPI0513303A8 (pt) | 2004-07-13 | 2005-06-21 | Uso de l-carnitina para o tratamento de doenças cardiovasculares |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7879908B2 (enExample) |
| EP (1) | EP1773314B1 (enExample) |
| JP (1) | JP5230195B2 (enExample) |
| KR (1) | KR101296479B1 (enExample) |
| CN (2) | CN101087602B (enExample) |
| AT (1) | ATE542529T1 (enExample) |
| AU (1) | AU2005262050B2 (enExample) |
| BR (1) | BRPI0513303A8 (enExample) |
| CA (1) | CA2569888C (enExample) |
| CY (1) | CY1112686T1 (enExample) |
| DK (1) | DK1773314T3 (enExample) |
| ES (1) | ES2380913T3 (enExample) |
| HR (1) | HRP20120178T1 (enExample) |
| IT (1) | ITRM20040346A1 (enExample) |
| ME (1) | ME01345B (enExample) |
| MX (1) | MXPA06014665A (enExample) |
| PL (1) | PL1773314T3 (enExample) |
| PT (1) | PT1773314E (enExample) |
| RS (1) | RS52253B (enExample) |
| SI (1) | SI1773314T1 (enExample) |
| WO (1) | WO2006005415A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| JPS6415220A (en) | 1987-07-06 | 1989-01-19 | Mitsubishi Electric Corp | Tension control device for utilizing maximum torque and maximum electric current of winding motor |
| JPH06102624B2 (ja) * | 1990-08-10 | 1994-12-14 | アース製薬株式会社 | 非心臓由来の不整脈防止薬 |
| IT1261695B (it) * | 1993-06-02 | 1996-05-29 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono. |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| WO2000030637A1 (en) * | 1998-11-26 | 2000-06-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
| KR100642731B1 (ko) * | 1999-10-11 | 2006-11-03 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 의료용 용액에서 삼투제로서 ｌ-카르니틴 및 그의알카노일 유도체의 용도 |
| JP4674046B2 (ja) * | 2002-04-01 | 2011-04-20 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | グルコース利用を刺激する化合物および使用方法 |
| ITRM20030178A1 (it) | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
-
2004
- 2004-07-13 IT IT000346A patent/ITRM20040346A1/it unknown
-
2005
- 2005-06-21 SI SI200531481T patent/SI1773314T1/sl unknown
- 2005-06-21 PL PL05755616T patent/PL1773314T3/pl unknown
- 2005-06-21 CN CN2005800234751A patent/CN101087602B/zh not_active Expired - Fee Related
- 2005-06-21 EP EP05755616A patent/EP1773314B1/en not_active Expired - Lifetime
- 2005-06-21 MX MXPA06014665A patent/MXPA06014665A/es not_active Application Discontinuation
- 2005-06-21 CA CA2569888A patent/CA2569888C/en not_active Expired - Lifetime
- 2005-06-21 JP JP2007520688A patent/JP5230195B2/ja not_active Expired - Fee Related
- 2005-06-21 AT AT05755616T patent/ATE542529T1/de active
- 2005-06-21 KR KR1020077000711A patent/KR101296479B1/ko not_active Expired - Fee Related
- 2005-06-21 BR BRPI0513303A patent/BRPI0513303A8/pt not_active Application Discontinuation
- 2005-06-21 ES ES05755616T patent/ES2380913T3/es not_active Expired - Lifetime
- 2005-06-21 PT PT05755616T patent/PT1773314E/pt unknown
- 2005-06-21 CN CN201110226409.1A patent/CN102349923B/zh not_active Expired - Fee Related
- 2005-06-21 HR HRP20120178TT patent/HRP20120178T1/hr unknown
- 2005-06-21 WO PCT/EP2005/006657 patent/WO2006005415A2/en not_active Ceased
- 2005-06-21 US US11/629,202 patent/US7879908B2/en not_active Expired - Lifetime
- 2005-06-21 AU AU2005262050A patent/AU2005262050B2/en not_active Ceased
- 2005-06-21 ME MEP-2012-32A patent/ME01345B/me unknown
- 2005-06-21 DK DK05755616.9T patent/DK1773314T3/da active
- 2005-06-21 RS RS20120095A patent/RS52253B/sr unknown
-
2010
- 2010-12-20 US US12/972,617 patent/US8394854B2/en not_active Expired - Fee Related
-
2012
- 2012-04-05 CY CY20121100341T patent/CY1112686T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaspan et al. | Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function | |
| Ravin et al. | Fatal cardiac event following initiation of risperidone therapy | |
| ES2577930T3 (es) | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 | |
| FI3628319T3 (fi) | Hepaattisen enkefalopatian hoito rifaksimiinilla | |
| AR040682A1 (es) | Forma de dosificacion una vez al dia de pramipexol | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| EA200971073A1 (ru) | Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| CY1112686T1 (el) | Χρηση l-καρνιτινης για τη θεραπεια καρδιαγγειακων νοσηματων | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| PT1408977E (pt) | Terapia de combinacao para o tratamento de falha cardiaca | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| BRPI0406552A (pt) | Uso de l-carnitina para o tratamento de doenças cardiovasculares | |
| Haessler et al. | 2009 pandemic H1N1-associated myocarditis in a previously healthy adult | |
| BRPI0414112A (pt) | uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono | |
| JP2006045200A (ja) | 間質性膀胱炎の治療薬 | |
| CY1114250T1 (el) | Ακετυλ l-καρνιτινη για την προληψη της επιπονης περιφερικης διαβητικης νευροπαθειας | |
| Prabhu et al. | Digital gangrene due to dopamine infusion-a case report | |
| McDaniel | Antidepressant activity of linezolid | |
| Kurlan | Declining medication requirement in some patients with advanced Parkinson disease and dementia | |
| Ortega Chavarría et al. | Neuroleptic malignant syndrome | |
| JP2022546134A (ja) | 自閉症スペクトル障害の治療における使用のためのバフィデムスタット | |
| Shankar et al. | Hyperglycemia induced hemichoreoathetosis, an uncommon presenting symptom of diabetes mellitus | |
| JP2008517872A5 (enExample) | ||
| Placebo-Controlled | Original Research Efficacy and Safety of Adjunctive Armodafinil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ALFASIGMA S.P.A. (IT) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |